Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Angelo Maria Patti, Rosaria Vincenza Giglio, Nikolaos Papanas, Manfredi Rizzo & Ali A. Rizvi. (2019) Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 12:2, pages 129-143.
Read now
Read now
Maka S Hedrington, Ana Tsiskarishvili & Stephen N Davis. (2018) Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. Expert Opinion on Biological Therapy 18:3, pages 343-351.
Read now
Read now
Robert S. Busch & Michael P. Kane. (2017) Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgraduate Medicine 129:7, pages 686-697.
Read now
Read now
Marc S. Rendell. (2016) Albiglutide: a unique GLP-1 receptor agonist. Expert Opinion on Biological Therapy 16:12, pages 1557-1569.
Read now
Read now
L. H. Chuang, B. G. Verheggen, M. Charokopou, D. Gibson, S. Grandy & B. Kartman. (2016) Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. Journal of Medical Economics 19:12, pages 1127-1134.
Read now
Read now
Leigh MacConell, Kate Gurney, Jaret Malloy, Ming Zhou & Orville Kolterman. (2015) Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes, Metabolic Syndrome and Obesity 8, pages 241-253.
Read now
Read now
Aditya Goud, Jixin Zhong & Sanjay Rajagopalan. (2015) Emerging utility of once-weekly exenatide in patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 8, pages 505-512.
Read now
Read now
Daisuke Yabe & Yutaka Seino. (2014) Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 9:6, pages 659-670.
Read now
Read now
Articles from other publishers (39)
Juan J. Gorgojo-Martínez, Pedro Mezquita-Raya, Juana Carretero-Gómez, Almudena Castro, Ana Cebrián-Cuenca, Alejandra de Torres-Sánchez, María Dolores García-de-Lucas, Julio Núñez, Juan Carlos Obaya, María José Soler, José Luis Górriz & Miguel Ángel Rubio-Herrera. (2022) Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine 12:1, pages 145.
Crossref
Crossref
Lawrence Blonde, Guillermo E. Umpierrez, S. Sethu Reddy, Janet B. McGill, Sarah L. Berga, Michael Bush, Suchitra Chandrasekaran, Ralph A. DeFronzo, Daniel Einhorn, Rodolfo J. Galindo, Thomas W. Gardner, Rajesh Garg, W. Timothy Garvey, Irl B. Hirsch, Daniel L. Hurley, Kenneth Izuora, Mikhail Kosiborod, Darin Olson, Shailendra B. Patel, Rodica Pop-Busui, Archana R. Sadhu, Susan L. Samson, Carla Stec, William V. TamborlaneJr.Jr., Katherine R. Tuttle, Christine Twining, Adrian Vella, Priyathama Vellanki & Sandra L. Weber. (2022) American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocrine Practice 28:10, pages 923-1049.
Crossref
Crossref
Xuexue Zhang, Miaoran Wang, Xujie Wang, Zhengchuan Zhu, Wantong Zhang, Zhongyang Zhou, Wei Tang & Qiuyan Li. (2022) Comparison of New Glucose-Lowering Drugs on the Risk of Pancreatitis in Type 2 Diabetes: A Network Meta-Analysis. Endocrine Practice 28:3, pages 333-341.
Crossref
Crossref
Courtney A. Zulauf-McCurdy, Stefany J. Coxe, Aaron R. Lyon, Ben Aaronson, Mercedes Ortiz & Margaret H. Sibley. (2021) Study protocol of a randomised trial of Summer STRIPES: a peer-delivered high school preparatory intervention for students with ADHD. BMJ Open 11:8, pages e045443.
Crossref
Crossref
Charalampos I. Liakos, Dimitrios P. Papadopoulos, Elias A. Sanidas, Maria I. Markou, Erifili E. Hatziagelaki, Charalampos A. Grassos, Maria L. Velliou & John D. Barbetseas. (2020) Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors). American Journal of Cardiovascular Drugs 21:2, pages 123-137.
Crossref
Crossref
Fei Gao, Xiaofeng Lv, Zhaohui Mo, Jianhua Ma, Qiu Zhang, Gangyi Yang, Weijuan Liu, Quanmin Li, Jian Zhou, Yuqian Bao & Weiping Jia. (2020) Efficacy and safety of polyethylene glycol loxenatide as add‐on to metformin in patients with type 2 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3b trial. Diabetes, Obesity and Metabolism 22:12, pages 2375-2383.
Crossref
Crossref
Alexandros Sachinidis, Dragana Nikolic, Anca Pantea Stoian, Nikolaos Papanas, Omer Tarar, Ali A. Rizvi & Manfredi Rizzo. (2020) Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism 111, pages 154343.
Crossref
Crossref
Giulia Di Dalmazi, Sara Coluzzi, Maria P.A. Baldassarre, Sofia Elena Sorbo, Stefania Dell’Aquila, Fabrizio Febo, Federica Ginestra, Giusi Graziano, Maria C. Rossi, Agostino Consoli & Gloria Formoso. (2020) Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting. Clinical Therapeutics 42:9, pages 1738-1749.e1.
Crossref
Crossref
Gianluca Svegliati-Baroni, Bárbara Patrício, Gessica Lioci, Maria Paula Macedo & Amalia Gastaldelli. (2020) Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. International Journal of Molecular Sciences 21:16, pages 5820.
Crossref
Crossref
Lalita Dahiya, Ramandeep Kaur, Rajiv Kumar, Manoj Kumar & Kezia Palta. (2020) GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus. Current Diabetes Reviews 16:4, pages 279-292.
Crossref
Crossref
Angelo Maria Patti, Ali A Rizvi, Rosaria Vincenza Giglio, Anca Pantea Stoian, Daniela Ligi & Ferdinando Mannello. (2020) Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. Journal of Clinical Medicine 9:4, pages 912.
Crossref
Crossref
Sanjay Kalra, Ashok Kumar Das, Rakesh Kumar Sahay, Manash Pratim Baruah, Mangesh Tiwaskar, Sambit Das, Sudip Chatterjee, Banshi Saboo, Ganapathi Bantwal, Saptarshi Bhattacharya, Gagan Priya, Manoj Chawla, Kiraninder Brar, Syed Abbas Raza, Azizul Hasan Aamir, Dina Shrestha, Noel Somasundaram, Prasad Katulanda, Faria Afsana, Shahjada Selim, Mohammad Wali Naseri, Ali Latheef & Manilka Sumanatilleke. (2019) Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. Diabetes Therapy 10:5, pages 1645-1717.
Crossref
Crossref
Raffaella Gentilella, Irene Romera, Claudia Nicolay, Raffaella Buzzetti, Luis Alberto Vázquez & Giorgio Sesti. (2019) Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents. Diabetes Therapy 10:3, pages 1113-1125.
Crossref
Crossref
Angelo Maria Patti, Dragana Nikolic, Antonio Magan-Fernandez, Rosaria Vincenza Giglio, Giuseppa Castellino, Roberta Chianetta, Roberto Citarrella, Egle Corrado, Francesca Provenzano, Vincenzo Provenzano, Giuseppe Montalto, Ali A. Rizvi & Manfredi Rizzo. (2019) Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. Diabetes Research and Clinical Practice 149, pages 163-169.
Crossref
Crossref
Patrick M. Jedlowski, Charisse H. Te, Robert J. Segal & Maryam T. Fazel. (2018) Cutaneous Adverse Effects of Diabetes Mellitus Medications and Medical Devices: A Review. American Journal of Clinical Dermatology 20:1, pages 97-114.
Crossref
Crossref
Kayla Riswold & Valerie Flynn. (2018) Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone. JAAD Case Reports 4:8, pages 830-832.
Crossref
Crossref
Manfredi Rizzo, Dragana Nikolic, Angelo Maria Patti, Carlo Mannina, Giuseppe Montalto, Brooke S. McAdams, Ali A. Rizvi & Francesco Cosentino. (2018) GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1864:9, pages 2814-2821.
Crossref
Crossref
Anita M. Loughlin, Qing Qiao, Anthony P. Nunes, Stephen M. Ezzy, Laura Yochum, C. Robin Clifford, Robert V. Gately, David D. Dore & John D. Seeger. (2018) Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States. Diabetes Spectrum 31:2, pages 129-137.
Crossref
Crossref
Anita M. Loughlin, Qing Qiao, Anthony P. Nunes, Peter Öhman, Stephen Ezzy, Laura Yochum, C. Robin Clifford, Robert Gately, David D. Dore & John D. Seeger. (2018) Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States. Diabetes, Obesity and Metabolism 20:4, pages 898-909.
Crossref
Crossref
Juan José Gorgojo-Martínez, Manuel Angel Gargallo-Fernández, Miguel Brito-Sanfiel & Arturo Lisbona-Catalán. (2018) Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project. International Journal of Clinical Practice 72:3, pages e13055.
Crossref
Crossref
B. Gallwitz. (2017) Rezeptoragonisten des „glucagon-like peptide 1”Receptor agonists of glucagon-like peptide 1. Der Diabetologe 13:7, pages 487-497.
Crossref
Crossref
Julie A. Lovshin. (2017) Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. Canadian Journal of Diabetes 41:5, pages 524-535.
Crossref
Crossref
Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz, Vivian P. Thompson, Yuliya Lokhnygina, John B. Buse, Juliana C. Chan, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Aldo P. Maggioni, Steven P. Marso, Peter Öhman, Neha J. Pagidipati, Neil Poulter, Ambady Ramachandran, Bernard Zinman & Adrian F. Hernandez. (2017) Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 377:13, pages 1228-1239.
Crossref
Crossref
Maria Assunta Potenza, Carmela Nacci, Maria Antonietta De Salvia, Luca Sgarra, Massimo Collino & Monica Montagnani. (2017) Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options. Pharmacological Research 120, pages 226-241.
Crossref
Crossref
Qiuhe Ji. (2017) Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists. Clinical Therapeutics 39:6, pages 1244-1264.
Crossref
Crossref
Julie A. Lovshin. (2017) WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. Canadian Journal of Diabetes.
Crossref
Crossref
Feng-fei Li, Lanlan Jiang, Liyuan Fu, Hong-hong Zhu, Peihua Zhou, Danfeng Zhang, Xiao-fei Su, Jin-dan Wu, Lei Ye & Jian-hua Ma. (2016) Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial. Diabetes Therapy 8:1, pages 177-187.
Crossref
Crossref
Juan P. Frías, Samer Nakhle, James A. Ruggles, Sergey Zhuplatov, Eric Klein, Rong Zhou & Poul Strange. (2017) Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes, Obesity and Metabolism 19:1, pages 40-48.
Crossref
Crossref
Carol H. Wysham, Leigh MacConell & Elise Hardy. (2016) Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial. Diabetes Care 39:10, pages 1768-1776.
Crossref
Crossref
Sandro Gentile, Felice Strollo & Antonio Ceriello. (2016) Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear?. Diabetes Therapy 7:3, pages 401-409.
Crossref
Crossref
Robert A. ScottDaniel F. FreitagLi LiAudrey Y. ChuPraveen SurendranRobin YoungNiels GrarupAlena StancákováYuning ChenTibor V. VargaHanieh YaghootkarJian’an LuanJing Hua ZhaoSara M. WillemsJennifer WesselShuai WangNisa MaruthurKyriaki MichailidouAilith PirieSven J. van der LeeChristopher GillsonAli Amin Al OlamaPhilippe AmouyelLarraitz ArriolaDominique ArveilerIciar Aviles-OlmosBeverley BalkauAurelio BarricarteInês BarrosoSara Benlloch GarciaJoshua C. BisStefan BlankenbergMichael BoehnkeHeiner BoeingEric BoerwinkleIngrid B. BoreckiJette Bork-JensenSarah BowdenCarlos CaldasMuriel CaslakeL. Adrienne CupplesCarlos CruchagaJacek CzajkowskiMarcel den HoedJanet A. DunnHelena M. EarlGeorg B. EhretEle FerranniniJean FerrieresThomas FoltynieIan FordNita G. ForouhiFrancesco GianfagnaCarlos GonzalezSara GrioniLouise HillerJan-Håkan JanssonMarit E. JørgensenJ. Wouter JukemaRudolf KaaksFrank KeeNicola D. KerrisonTimothy J. KeyJukka KonttoZsofia Kote-JaraiAldi T. KrajaKari KuulasmaaJohanna KuusistoAllan LinnebergChunyu LiuGaëlle MarenneKaren L. MohlkeAndrew P. MorrisKenneth MuirMartina Müller-NurasyidPatricia B. MunroeCarmen NavarroSune F. NielsenPeter M. NilssonBørge G. NordestgaardChris J. PackardDomenico PalliSalvatore PanicoGina M. PelosoMarkus PerolaAnnette PetersChristopher J. PooleJ. Ramón QuirósOlov RolandssonCarlotta SacerdoteVeikko SalomaaMaría-José SánchezNaveed SattarStephen J. SharpRebecca SimsNadia SlimaniJennifer A. SmithDeborah J. ThompsonStella TrompetRosario TuminoDaphne L. van der AYvonne T. van der SchouwJarmo VirtamoMark WalkerKlaudia WalterJean E. AbrahamLaufey T. AmundadottirJennifer L. AponteAdam S. ButterworthJosée DupuisDouglas F. EastonRosalind A. EelesJeanette ErdmannPaul W. FranksTimothy M. FraylingTorben HansenJoanna M. M. HowsonTorben JørgensenJaspal KoonerMarkku LaaksoClaudia LangenbergMark I. McCarthyJames S. PankowOluf PedersenElio RiboliJerome I. RotterDanish SaleheenNilesh J. SamaniHeribert SchunkertPeter VollenweiderStephen O’RahillyPanos DeloukasJohn DaneshMark O. GoodarziSekar KathiresanJames B. MeigsMargaret G. EhmNicholas J. WarehamDawn M. Waterworth. (2016)
A genomic approach to therapeutic target validation identifies a glucose-lowering
GLP1R
variant protective for coronary heart disease
. Science Translational Medicine 8:341.
Crossref
Crossref
Michael E. Trautmann, Jenny Han & James Ruggles. (2016) Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data. Clinical Therapeutics 38:6, pages 1464-1473.
Crossref
Crossref
Hui Peng, Laura L. Want & Vanita R. Aroda. (2016) Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. Current Diabetes Reports 16:5.
Crossref
Crossref
Stephen Brunton & Jaime A. Davidson. (2016) Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes. Clinical Therapeutics 38:3, pages 582-594.
Crossref
Crossref
Curtis TriplittCarolina Solis-Herrera. (2015) GLP-1 Receptor Agonists. The Diabetes Educator 41:1_suppl, pages 32S-46S.
Crossref
Crossref
Susan LaRue & Jaret Malloy. (2015) Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes. Journal of Diabetes Science and Technology 9:4, pages 815-821.
Crossref
Crossref
Yahiya Y. Syed & Paul L. McCormack. (2015) Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus. Drugs 75:10, pages 1141-1152.
Crossref
Crossref
Jennifer D. Goldman-Levine. (2015) Combination Therapy When Metformin Is Not an Option for Type 2 Diabetes. Annals of Pharmacotherapy 49:6, pages 688-699.
Crossref
Crossref
J.J. Gorgojo-Martínez. (2014) Nuevos fármacos antidiabéticos: avanzando hacia el control integral de la diabesidad. Hipertensión y Riesgo Vascular 31:2, pages 45-57.
Crossref
Crossref